Feb. 16 Quick Takes: $73M series A for Walking Fish

Walking Fish Therapeutics Inc. topped off its $50 million series A financing of last September with new investments from Northpond Ventures and First Spark Ventures, with support from Terra Magnum Capital Partners. The company has now raised a total of $73 million, and will use the funds to advance its pipeline of B cell therapeutics for cancer, rare disease, regenerative medicine, autoimmune disease and recombinant antibody production. Walking Fish was co-founded by CEO Lewis “Rusty” Williams, who also co-founded Five Prime Therapeutics Inc. in 2002.

Parse Biosciences Inc. intends to use its newly raised $41.5 million series B round to fund commercialization of its Evercode Whole Transcriptome single-cell sequencing products and expand the applications of the platform beyond transcriptomics. The financing, which was co-led by Marshall Wace and Janus Henderson and had participation from Soleus Capital, Logos Capital and Bioeconomy Capital, brings Parse’s total funding to $50 million. ...